X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2019-12-09 | CRL | Charles River Laboratories International, Inc. | Girshick Birgit | Corporate EVP | S - Sale | $145.55 | -1,051 | 17,715 | -6% | -$152,972 | ||||||
2019-12-09 | CRL | Charles River Laboratories International, Inc. | Girshick Birgit | Corporate EVP | S - Sale | $144.93 | -2,874 | 18,766 | -13% | -$416,516 | ||||||
2019-12-09 | CRL | Charles River Laboratories International, Inc. | Girshick Birgit | Corporate EVP | S - Sale | $144.21 | -2,420 | 21,640 | -10% | -$348,993 | ||||||
D | 2019-12-03 | EXEL | Exelixis, Inc. | Schwab Gisela | Pres, Prod Dev, Med Aff, CMO | S - Sale+OE | $16.22 | -50,000 | 328,437 | -13% | -$811,000 | |||||
2019-12-02 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $63.94 | -1,400 | 6,517,679 | 0% | -$89,514 | ||||||
DM | 2019-11-29 | INCY | Incyte Corp | Wenqing Yao | EVP, Head of Discovery Chem | S - Sale+OE | $95.00 | -20,000 | 95,308 | -17% | -$1,900,000 | |||||
DM | 2019-11-29 | INCY | Incyte Corp | Iyengar Vijay K | EVP GPS, BD, Licensing | S - Sale+OE | $95.00 | -7,866 | 17,609 | -31% | -$747,270 | |||||
DM | 2019-11-29 | INCY | Incyte Corp | Flannelly Barry P | EVP, GM US | S - Sale+OE | $95.00 | -7,182 | 16,979 | -30% | -$682,290 | |||||
2019-12-02 | INTI | Inhibitor Therapeutics, Inc. | Hasara Garrison J. | CFO, Treasurer | P - Purchase | $0.07 | +13,500 | 3,972,544 | 0% | +$945 | ||||||
M | 2019-11-27 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $63.98 | -7,453 | 6,519,079 | 0% | -$476,850 | |||||
M | 2019-10-28 | BUDZ | Weed, Inc. | Breen Nicole M | Secretary, Treasurer, 10% | S - Sale | $0.40 | -66,000 | 23,563,421 | 0% | -$26,280 | |||||
M | 2019-10-09 | BUDZ | Weed, Inc. | Breen Nicole M | Secretary, Treasurer, 10% | S - Sale | $0.40 | -64,580 | 23,629,421 | 0% | -$25,712 | |||||
M | 2019-11-25 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $63.98 | -5,941 | 6,526,532 | 0% | -$380,103 | |||||
D | 2019-11-25 | INCY | Incyte Corp | Flannelly Barry P | EVP, GM US | S - Sale+OE | $90.00 | -2,142 | 16,979 | -11% | -$192,780 | |||||
D | 2019-11-25 | INCY | Incyte Corp | Wenqing Yao | EVP, Head of Discovery Chem | S - Sale+OE | $90.00 | -15,000 | 95,308 | -14% | -$1,350,000 | |||||
D | 2019-11-25 | INCY | Incyte Corp | Trower Paul | Principal Accounting Officer | S - Sale+OE | $90.00 | -15,000 | 17,306 | -46% | -$1,350,000 | |||||
2019-11-21 | EXAS | Exact Sciences Corp | Cole G Bradley | GM - Diagnostics | S - Sale | $80.38 | -28,016 | 43,321 | -39% | -$2,251,926 | ||||||
M | 2019-11-21 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $63.87 | -1,800 | 6,532,473 | 0% | -$114,970 | |||||
M | 2019-11-19 | NRC | National Research Corp | Mowry Barbara | Dir | S - Sale | $62.49 | -14,785 | 6,902 | -68% | -$923,871 | |||||
D | 2019-11-15 | INCY | Incyte Corp | Swain Paula J | EVP, HR | S - Sale+OE | $86.46 | -2,500 | 41,612 | -6% | -$216,150 | |||||
M | 2019-11-15 | NRC | National Research Corp | Mowry Barbara | Dir | S - Sale | $61.86 | -3,215 | 21,687 | -13% | -$198,865 | |||||
M | 2019-11-13 | NRC | National Research Corp | Mowry Barbara | Dir | S - Sale | $61.73 | -7,762 | 24,902 | -24% | -$479,158 | |||||
2019-11-13 | CRL | Charles River Laboratories International, Inc. | Girshick Birgit | Corporate EVP | S - Sale | $137.23 | -1,499 | 24,060 | -6% | -$205,712 | ||||||
D | 2019-11-13 | CRL | Charles River Laboratories International, Inc. | Girshick Birgit | Corporate EVP | S - Sale+OE | $137.04 | -8,105 | 25,559 | -24% | -$1,110,717 | |||||
2019-11-08 | GHDX | Genomic Health Inc | Exact Sciences Corp | See Footnotes, 10% | P - Purchase | $0.00 | +37,643,330 | 100 | -100% | +$0 | ||||||
DM | 2019-11-06 | INCY | Incyte Corp | Dixon Wendy L | Dir | S - Sale+OE | $83.92 | -53,334 | 12,340 | -81% | -$4,475,774 | |||||
D | 2019-11-04 | EXEL | Exelixis, Inc. | Schwab Gisela | Pres, Prod Dev, Med Aff, CMO | S - Sale+OE | $15.99 | -50,000 | 339,211 | -13% | -$799,500 | |||||
D | 2019-11-01 | INCY | Incyte Corp | Wenqing Yao | EVP, Head of Discovery Chem | S - Sale+OE | $85.00 | -7,960 | 95,308 | -8% | -$676,600 | |||||
D | 2019-11-01 | INCY | Incyte Corp | Trower Paul | Principal Accounting Officer | S - Sale+OE | $85.00 | -8,500 | 17,306 | -33% | -$722,500 | |||||
D | 2019-10-29 | INCY | Incyte Corp | Wenqing Yao | EVP, Head of Discovery Chem | S - Sale+OE | $85.00 | -2,040 | 95,308 | -2% | -$173,400 | |||||
D | 2019-10-29 | INCY | Incyte Corp | Trower Paul | Principal Accounting Officer | S - Sale+OE | $80.45 | -16,500 | 17,306 | -49% | -$1,327,500 | |||||
2019-10-29 | INCY | Incyte Corp | Iyengar Vijay K | EVP GPS, BD, Licensing | S - Sale | $85.00 | -930 | 17,609 | -5% | -$79,050 | ||||||
D | 2019-10-22 | INCY | Incyte Corp | Swain Paula J | EVP, HR | S - Sale+OE | $80.00 | -2,500 | 41,612 | -6% | -$200,000 | |||||
2019-10-18 | MEDP | Medpace Holdings, Inc. | Ewald Stephen P | GC, Corp. Secy. | S - Sale | $77.30 | -8,000 | 0 | -100% | -$618,400 | ||||||
M | 2019-10-14 | MEDP | Medpace Holdings, Inc. | Geiger Jesse J | CFO, COO, Lab Operations | S - Sale | $79.16 | -16,800 | 31,348 | -35% | -$1,329,816 | |||||
2019-10-10 | EXEL | Exelixis, Inc. | Haley Patrick J. | SVP, Commercial | S - Sale | $16.27 | -303 | 123,396 | 0% | -$4,930 | ||||||
M | 2019-09-19 | BUDZ | Weed, Inc. | Breen Nicole M | Secretary, Treasurer, 10% | S - Sale | $0.41 | -65,334 | 23,694,001 | 0% | -$26,460 | |||||
M | 2019-09-11 | BUDZ | Weed, Inc. | Breen Nicole M | Secretary, Treasurer, 10% | S - Sale | $0.45 | -29,604 | 23,759,345 | 0% | -$13,453 | |||||
M | 2019-08-30 | BUDZ | Weed, Inc. | Breen Nicole M | Secretary, Treasurer, 10% | S - Sale | $0.41 | -46,000 | 23,788,949 | 0% | -$18,875 | |||||
D | 2019-09-25 | NRC | National Research Corp | Jackson Steven D. | Pres | S - Sale+OE | $59.15 | -4,010 | 89,586 | -4% | -$237,195 | |||||
D | 2019-10-02 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $17.66 | -26,364 | 416,875 | -6% | -$465,588 | |||||
D | 2019-10-01 | EXEL | Exelixis, Inc. | Schwab Gisela | Pres, Prod Dev, Med Aff, CMO | S - Sale+OE | $17.87 | -30,000 | 339,211 | -8% | -$536,100 | |||||
D | 2019-10-01 | XON | Intrexon Corp | Perez Jeffrey Thomas | SVP, IP Affairs | S - Sale+OE | $5.50 | -4,521 | 52,365 | -8% | -$24,847 | |||||
D | 2019-10-01 | XON | Intrexon Corp | Reed Thomas D. | Chief Science Officer | S - Sale+OE | $5.50 | -3,658 | 224,762 | -2% | -$20,104 | |||||
D | 2019-10-01 | XON | Intrexon Corp | Sterling Rick L. | CFO | S - Sale+OE | $5.50 | -4,521 | 114,449 | -4% | -$24,847 | |||||
D | 2019-10-01 | XON | Intrexon Corp | Sabzevari Helen | Pres, Precigen, Inc. | S - Sale+OE | $5.50 | -5,005 | 71,677 | -7% | -$27,507 | |||||
D | 2019-10-01 | XON | Intrexon Corp | Bostick Thomas | COO | S - Sale+OE | $5.50 | -4,521 | 45,697 | -9% | -$24,847 | |||||
D | 2019-10-01 | XON | Intrexon Corp | Lehr Donald P. | GC | S - Sale+OE | $5.50 | -5,001 | 66,816 | -7% | -$27,485 | |||||
D | 2019-09-25 | NRC | National Research Corp | Jackson Steven D. | Pres | S - Sale+OE | $60.79 | -4,000 | 93,596 | -4% | -$243,156 | |||||
D | 2019-09-20 | NRC | National Research Corp | Jackson Steven D. | Pres | S - Sale+OE | $63.20 | -2,500 | 97,596 | -2% | -$158,000 | |||||
D | 2019-09-18 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $19.20 | -37,227 | 407,830 | -8% | -$714,758 | |||||
2019-09-19 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $63.15 | -6,200 | 6,534,273 | 0% | -$391,531 | ||||||
D | 2019-09-19 | NRC | National Research Corp | Jackson Steven D. | Pres | S - Sale+OE | $63.50 | -380 | 100,096 | 0% | -$24,130 | |||||
D | 2019-09-18 | INCY | Incyte Corp | Swain Paula J | EVP, HR | S - Sale+OE | $80.00 | -2,500 | 41,612 | -6% | -$200,000 | |||||
2019-09-17 | INCY | Incyte Corp | Flannelly Barry P | EVP, GM US | S - Sale | $77.71 | -2,491 | 16,757 | -13% | -$193,576 | ||||||
D | 2019-09-18 | NRC | National Research Corp | Jackson Steven D. | Pres | S - Sale+OE | $62.00 | -2,500 | 100,476 | -2% | -$155,000 | |||||
2019-09-18 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $60.50 | -500,000 | 6,540,473 | -7% | -$30,252,050 | ||||||
D | 2019-09-17 | NRC | National Research Corp | Berwick Donald M | Dir | S - Sale+OE | $61.99 | -6,992 | 0 | -100% | -$433,437 | |||||
D | 2019-09-17 | NRCIA | National Research Corp | Jackson Steven D. | Pres | S - Sale+OE | $62.00 | -2,500 | 102,976 | -2% | -$155,000 | |||||
D | 2019-09-16 | NRC | National Research Corp | Berwick Donald M | Dir | S - Sale+OE | $62.04 | -6,989 | 6,992 | -50% | -$433,583 | |||||
2019-09-13 | BASI | Bioanalytical Systems Inc | Leasure Robert Jr. | Pres, CEO | P - Purchase | $3.72 | +26,846 | 164,965 | +19% | +$99,867 | ||||||
2019-09-13 | BASI | Bioanalytical Systems Inc | Oakley Daniel Thomas | COO | P - Purchase | $3.65 | +1,000 | 48,546 | +2% | +$3,650 | ||||||
2019-09-13 | BASI | Bioanalytical Systems Inc | Pitchford William D | CHRO | P - Purchase | $3.70 | +12,000 | 22,000 | +120% | +$44,400 | ||||||
D | 2019-09-13 | NRC | National Research Corp | Berwick Donald M | Dir | S - Sale+OE | $61.99 | -2,924 | 13,981 | -17% | -$181,259 | |||||
D | 2019-09-12 | EXAS | Exact Sciences Corp | Johnson Scott C. | SVP - Research, Development | S - Sale+OE | $108.63 | -3,527 | 12,504 | -22% | -$383,138 | |||||
D | 2019-09-12 | NRC | National Research Corp | Berwick Donald M | Dir | S - Sale+OE | $61.99 | -1,120 | 16,905 | -6% | -$69,429 | |||||
2019-09-10 | EXEL | Exelixis, Inc. | Haley Patrick J. | SVP, Commercial | S - Sale | $18.84 | -1,000 | 119,640 | -1% | -$18,840 | ||||||
2019-09-10 | BASI | Bioanalytical Systems Inc | Perrow Wendy | Dir | P - Purchase | $3.62 | +10,000 | 10,000 | New | +$36,200 | ||||||
2019-09-06 | PRAH | Pra Health Sciences, Inc. | Kkr Pra Investors L.P. | 10% | S - Sale | $97.41 | -6,666,684 | 0 | -100% | -$649,401,688 | ||||||
D | 2019-09-06 | NRC | National Research Corp | Karas Kevin R | SVP Finance, CFO, Treas, Secy | S - Sale+OE | $62.83 | -2,902 | 17,576 | -14% | -$182,338 | |||||
D | 2019-09-06 | NRC | National Research Corp | Berwick Donald M | Dir | S - Sale+OE | $63.01 | -9,035 | 18,025 | -33% | -$569,305 | |||||
M | 2019-09-04 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $6.54 | -171,701 | 864,330 | -17% | -$1,123,640 | |||||
M | 2019-09-05 | BASI | Bioanalytical Systems Inc | Oakley Daniel Thomas | COO | P - Purchase | $3.43 | +12,500 | 47,546 | +36% | +$42,925 | |||||
D | 2019-09-05 | NRC | National Research Corp | Karas Kevin R | SVP Finance, CFO, Treas, Secy | S - Sale+OE | $63.97 | -7,114 | 20,478 | -26% | -$455,055 | |||||
2019-09-04 | BASI | Bioanalytical Systems Inc | Leasure Robert Jr. | Pres, CEO | P - Purchase | $3.15 | +11,500 | 138,119 | +9% | +$36,225 | ||||||
2019-09-04 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $64.85 | -1,063 | 7,040,473 | 0% | -$68,932 | ||||||
M | 2019-08-30 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $6.37 | -136,899 | 1,036,031 | -12% | -$872,654 | |||||
2019-09-03 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $64.84 | -33,800 | 7,041,536 | 0% | -$2,191,545 | ||||||
2019-08-29 | BASI | Bioanalytical Systems Inc | Oakley Daniel Thomas | COO | P - Purchase | $2.69 | +5,000 | 36,046 | +16% | +$13,450 | ||||||
M | 2019-08-28 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $6.26 | -191,400 | 1,172,930 | -14% | -$1,198,458 | |||||
2019-08-29 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $64.89 | -2,800 | 7,075,336 | 0% | -$181,703 | ||||||
2019-08-28 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $63.00 | -252,000 | 7,078,136 | -3% | -$15,876,428 | ||||||
M | 2019-08-26 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $6.24 | -100,000 | 1,364,330 | -7% | -$623,567 | |||||
2019-08-23 | BASI | Bioanalytical Systems Inc | Oakley Daniel Thomas | COO | P - Purchase | $2.77 | +2,594 | 31,046 | +9% | +$7,185 | ||||||
M | 2019-08-21 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $6.06 | -100,000 | 1,464,330 | -6% | -$606,483 | |||||
M | 2019-08-21 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $64.83 | -12,648 | 7,330,136 | 0% | -$819,909 | |||||
M | 2019-08-19 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $6.03 | -100,000 | 1,564,330 | -6% | -$603,360 | |||||
2019-08-20 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $64.50 | -900 | 7,342,784 | 0% | -$58,050 | ||||||
D | 2019-08-16 | EXEL | Exelixis, Inc. | Hessekiel Jeffrey | EVP, GC | S - Sale+OE | $21.10 | -75,000 | 234,819 | -24% | -$1,582,500 | |||||
2019-08-19 | BASI | Bioanalytical Systems Inc | Leasure Robert Jr. | Pres, CEO | P - Purchase | $2.19 | +16,000 | 126,619 | +14% | +$35,040 | ||||||
D | 2019-08-16 | EXEL | Exelixis, Inc. | Poste George | Dir | S - Sale+OE | $20.50 | -25,000 | 112,792 | -18% | -$512,500 | |||||
2019-08-19 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $64.68 | -12,198 | 7,343,684 | 0% | -$788,943 | ||||||
D | 2019-08-15 | INCY | Incyte Corp | Swain Paula J | EVP, HR | S - Sale+OE | $80.96 | -2,500 | 41,612 | -6% | -$202,400 | |||||
2019-08-16 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $64.74 | -3,763 | 7,355,882 | 0% | -$243,623 | ||||||
D | 2019-08-14 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $20.11 | -35,040 | 376,795 | -9% | -$704,654 | |||||
M | 2019-08-14 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $5.58 | -79,305 | 1,664,330 | -5% | -$442,896 | |||||
M | 2019-08-14 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $64.72 | -19,000 | 7,359,645 | 0% | -$1,229,672 | |||||
2019-08-12 | EXEL | Exelixis, Inc. | Haley Patrick J. | SVP, Commercial | S - Sale | $20.39 | -1,000 | 120,640 | -1% | -$20,390 | ||||||
M | 2019-08-12 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $5.64 | -120,695 | 1,743,635 | -6% | -$680,414 | |||||
D | 2019-08-12 | CRL | Charles River Laboratories International, Inc. | Smith David Ross | Corporate EVP, CFO | S - Sale+OE | $130.36 | -1,249 | 18,078 | -6% | -$162,821 |
A | Amended filing |
D | Derivative transaction in filing (usually option exercise) |
E | Error detected in filing |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |